

MyBreastAI Suite*

One platform.

Powering endless possibilities.



GE HealthCare

Today's challenges

Heavy workloads. Limited staff.
You're consistently expected to
do more with less.

And the growing number of
breast cancer cases worldwide
only adds to the pressure.

1 in 8 women
will develop breast cancer¹

Incidence rates increasing
5% per year¹

Women with dense breasts
4 to 6 X more
likely to develop breast
cancer¹

20-40%
of breast cancers are missed²⁻⁵

77% High prevalence of
burnout among breast imagers⁶⁻⁷

71% Report stress of having
to practice faster than they
would like because of a high
volume of work⁶⁻⁷



One platform. Powering endless possibilities.

MyBreastAI Suite is a one-stop platform of proven AI apps to help accelerate breast cancer detection for peace of mind. Push your productivity with simplicity.

There is enough demand for your time and attention without the added hassle of finding, adopting, and maintaining multiple applications. MyBreastAI Suite offers a comprehensive collection of apps that assist you to personalize breast cancer screening.

MyBreastAI Suite initial release includes:

- ProFound AI® for DBT
- PowerLook® Density Assessment
- SecondLook for 2D Mammography



Best-in-class AI tools for breast cancer detection and density assessment



Simplify with one supplier for integration, training, service, and upgrades



Tailored to your facility's workflow

Increase sensitivity ProFound AI[®] for DBT


Trained with one of the largest available 3D image datasets, ProFound AI provides radiologists with crucial information, such as lesion Certainty of Finding and Case Scores, which assists in prioritizing caseload, clinical decision-making and may help to reduce physician burnout⁸.

The iCAD reader study shows that reading with ProFound AI:

By **8%** Increases reader sensitivity by 8%⁹

By **6.9%** Increases reader specificity by 6.9%⁹

Up to **52%** Decreases reading time by up to 52% compared to without¹⁰




Profound AI's Certainty of Findings scores assist in prioritizing caseload and clinical decision-making¹¹.

Standardized reportings

PowerLook[®] Density Assessment

Breast density assessment has traditionally been determined by the radiologist's visual assessment, but studies show these can vary - and clinicians may even disagree with their own assessment year to year. This can lead to unnecessary additional imaging, which can increase patient and facility costs¹².



PowerLook Density helps to:

- Standardize breast density assessment and reduce variability across multiple radiologists.¹²
- Simplify and standardize reporting and stratification for clinicians, with results clinicians can rely on.¹³
- Enable clinicians to provide women with accurate and reliable breast density assessments based on AI mammogram analysis.¹³




PowerLook[®]
DENSITY ASSESSMENT Version: 1

Patient Demographics

Patient Name: ROULAND^Fabienne Daniel Marie-Therese
Patient ID: 202010630RU
Patient DOB: 07/22/1972
Accession #: 27054213
Study Date: 08/17/2020 10:47:02 AM

C




iCAD[®]

Breast cancer detection

SecondLook

for 2D Mammography

The SecondLook Computer-Aided Detection (CAD) system for mammography is intended to identify and mark regions of interest on screening and diagnostic mammograms from GE HealthCare full-field digital mammography (FFDM) systems to bring them to the attention of the radiologist after an initial reading has been completed.¹⁴





Patient [0904, Pristina R Spic mass] 0904,
Pristina R Spic mass
DOB --, Apr 00YY
CAD: iCAD, Inc. 7.2.H 17.06.2020 17:43:28
Alg: iCAD PowerLook 7.2.H Alg: iCAD PowerLook 7.2.H
View: 1
R
MLO

ot [0904, Pristina R
Pr
CAD: iCAD, Inc. 7.2
PowerLook 7.2.H Alg:

12/21/2019

1cm

Outperform
today.
Prepare for
tomorrow.



Transform the way you work and experience more opportunities with MyBreastAI Suite.

Keep information private and secure

Protect what's important and minimize risk with built-in cybersecurity controls and ongoing guidance.



Amplify your impact

Experience the full power of Pristina Bright¹⁵ mammography innovations by leveraging MyBreastAI Suite as part of our single service offering.¹⁶



Expand your expertise

Advance your MyBreastAI Suite experience with our community resources and learning opportunities.



Get ahead. Stay ahead.

Expect quick and easy upgrades with the platform that is engineered for next-generation growth.



Maximize your MyBreastAI Suite experience

Plan for progress

Count on GE HealthCare to keep powering new possibilities along the entire breast care pathway.



References:

- * MyBreastAI suite is a commercial offering that includes an AI platform optimized for Mammography, ProFound AI for DBT, SecondLook for 2D Mammography and PowerLook® Density Assessment. These three applications are provided by iCAD. MyBreastAI Suite is compatible with the latest versions of iCAD, Inc. as of November 14, 2023.
1. Arnold M, Morgan E, Rungay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. *Breast*. 2022 Dec;66:15-23. doi: 10.1016/j.breast.2022.08.010. Epub 2022 Sep 2.
 2. Kalager M, Tamimi R, Bretthauer M et al. Prognosis in women with interval breast cancer: population based observational cohort study. *BMJ*. 2012;345: e7536. doi:10.1136/bmj.e7536.
 3. Marmot M, Altman G, Cameron A et al. The benefits and harms of breast cancer screening: an independent review. *Br J Cancer*. 2013; 108: 11, 2205-2240. doi: 10.1038/bjc.2013.177.
 4. Curry S, Krist A, Owens D. High-priority evidence gaps for clinical preventive services. U.S. Preventive Services Task Force. Published November 2018. Accessed May 11, 2021.
 5. Seely J and Alhassan, T. Screening for breast cancer in 2018—what should we be doing today? *Curr. Oncol*. 2018; 25: S115–S124. doi: 10.3747/co.25.3770.
 6. Parikh JR, Sun J, Mainiero MB. Prevalence of burnout in breast imaging radiologists. *J Breast Imaging*. 2020;2(2):112–116.
 7. Parikh JR, Sun J, Mainiero MB. What Causes the Most Stress in Breast Radiology Practice? A Survey of Members of the Society of Breast Imaging. *J Breast Imaging*. 2021 Apr 19;3(3):332-342. doi: 10.1093/jbi/wbab012.
 8. iCAD data on file. FDA filing: K203822. Standalone performance varies by vendor. FDA Cleared and CE Mark Pending. Reading times may vary based on the specific functionality of the viewing application used for interpretation.
 9. Reader performance with Profound AI compared to performance without. iCAD reader study: Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. *Radiology: Artificial Intelligence*. 1 (4). Accessed via <https://pubs.rsna.org/doi/10.1148/ryai.2019180096> iCAD labelling and user manual, DTM160 rev C.
 10. iCAD reader study: Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. *Radiology: Artificial Intelligence*. 1 (4). Accessed via <https://pubs.rsna.org/doi/10.1148/ryai.2019180096> iCAD labelling and user manual, DTM160 rev C. Reading times may vary based on the specific functionality of the viewing application used for interpretation.
 11. iCAD data on file. FDA filing: K203822. Standalone performance varies by vendor. FDA Cleared and CE Mark Pending. Reading times may vary based on the specific functionality of the viewing application used for interpretation.
 12. Sprague B, Conant E, Omega T et al. Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice: A Multicenter Observational Study. *Ann Intern Med*. 2016; 165(7):457-464. doi:10.7326/M15-2934.
 13. iCAD labelling and user manual, DTM135-1, DTM156 -3, DTM184 rev1.
 14. iCAD labelling and user manual, DTM103 - Revision C.
 15. Pristina Bright is a commercial offering that includes Senographe Pristina™, SenoBright™ HD and Serena Bright™.
 16. With a service contract.
- Product may not be available in all countries and regions. Full product technical specification is available upon request.

About GE HealthCare

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient's journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from prevention and screening, to diagnosis, treatment, therapy, and monitoring. We are an \$18 billion business with 51,000 employees working to create a world where healthcare has no limits.

Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website gehealthcare.com for more information.



© 2023 GE HealthCare.

GE is a trademark of General Electric Company used under trademark license.

iCAD, ProFound AI and PowerLook are trademarks of iCAD, Inc.

JB26479XX